Results from 6-month ActiPatch Product Observation Study

By Julie A. Vetalice

Results from a 6-month study observing BioElectronics' ActiPatch® musculoskeletal pain therapy device indicated an average 61% reduction in pain for >90% of participants, improved quality of life, a decrease in visits to the doctor or pain specialist, etc.

Of the 254 chronic pain sufferers that participated, 224 completed the full 6-month study.

Specifically, observed results included:

  • No side effects
  • Treatment durability: >90% of participants reported continued relief averaging a 61% reduction in pain, even after 6 months
  • Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity and 71% reported quality of life as "much better" to "a great deal better"
  • Decreased medication use: 86% reported a decrease in medication use that continued to improve over time, including prescription narcotic-based drugs
  • Decreased adverse events from medication use: 68% were experiencing adverse side effects; of these, 71% reported a reduction in adverse side effects
  • Healthcare savings: 65% spent less on pain therapies; 65% reported fewer visits to the doctor and pain specialist


The disposable, $30 ActiPatch device is an over-the-counter treatment for back pain and other musculoskeletal complaints.

Source: BioElectronics Corporation

Tags: Regulatory, Trial/Study